RoslinCT and BOOST Pharma partner to advance infant cell therapy for osteogenesis imperfecta

RoslinCT and BOOST Pharma Forge Strategic Partnership to Advance Groundbreaking Cell Therapy for Infants with Osteogenesis Imperfecta In a major step forward for pediatric rare disease therapy, RoslinCT, a globally recognized contract development and manufacturing organization (CDMO) specializing in advanced…












